1. Home
  2. About FDA
  3. FDA Organization
  4. Office of the Commissioner
  5. Office of the Chief Scientist
  6. Office of Occupational Safety and Health
  7. FDA Institutional Biosafety Committee
  1. Office of Occupational Safety and Health

FDA Institutional Biosafety Committee

The Food and Drug Administration (FDA) Institutional Biosafety Committee (IBC) plays a critical role in the risk management of FDA biomedical research by conducting initial and continuing peer reviews of laboratory activities and protocols. In addition, the FDA IBC ensures that applicable guidelines and policies are applied consistently to the review of in vivo and in vitro research involving recombinant or synthetic nucleic acid molecules.

In this role, the IBC collaborates with Subject Matter Experts (SMEs) from the Centers/Programs/Offices and the Office of Occupational Safety and Health (OOSH) to ensure that the benefit of laboratory research activities and protocols outweigh the risks and include appropriate biosafety and biosecurity measures to protect the safety and health of the employees, visitors, and surrounding communities. The aim of the IBC is to preserve the safety and health of the FDA workforce while maintaining operational efficiency and minimizing administrative delays. 

Back to Top